Welcome to our dedicated page for Lucid Diagnostics SEC filings (Ticker: LUCD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Lucid Diagnostics Inc. (NASDAQ: LUCD), a commercial-stage, cancer prevention medical diagnostics company focused on esophageal precancer detection in patients with gastroesophageal reflux disease (GERD). Through these filings, investors can review the company’s official disclosures on financial performance, capital structure, and material corporate events.
Current reports on Form 8-K document significant events such as quarterly financial results, public offerings of common stock, and board appointments. For example, Lucid has filed 8-Ks to furnish press releases announcing financial results for quarters ended June 30 and September 30, 2025, to report the entry into and closing of an underwritten public offering of common stock under a shelf registration statement on Form S-3, and to disclose the appointment of a new director designated by holders of its convertible secured promissory notes.
Periodic reports such as Forms 10-Q and 10-K, referenced in Lucid’s press releases and 8-K filings, contain detailed financial statements, management’s discussion and analysis, and additional information about its EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device business. These documents explain how the company reports EsoGuard-related revenues, operating expenses, and non-GAAP measures such as EBITDA and non-GAAP adjusted loss.
Investors can also find information on securities offerings and agreements in Lucid’s filings. An 8-K dated September 10, 2025 describes an underwriting agreement for an underwritten public offering of common stock, including the number of shares, public offering price, underwriting discount, and use of proceeds for working capital and general corporate purposes. A subsequent 8-K dated September 11, 2025 reports the closing of that offering and the expected net proceeds.
Stock Titan’s interface surfaces these SEC filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand the significance of each filing. Real-time updates from the EDGAR system ensure that new 8-Ks, 10-Qs, 10-Ks, and other forms are added as they are filed, while Form 4 and related insider transaction reports, when available, can be reviewed to analyze trading activity by Lucid’s officers, directors, or significant shareholders.
Lucid Diagnostics Inc. proposes to offer up to $25,000,000 of common stock through an at-the-market offering under a sales agreement with Maxim Group LLC.
The shares may be sold from time to time at prevailing market prices; Maxim will act as agent or principal and receive a 3.0% commission. Net proceeds, if any, are intended for working capital and general corporate purposes.
Lucid Diagnostics Inc. reported fourth quarter and full-year 2025 results and provided a business update centered on its EsoGuard esophageal DNA test. In 4Q25 the company processed 3,664 EsoGuard tests and generated $1.5 million in revenue.
For the quarter, operating expenses were $15.5 million and GAAP net loss attributable to common stockholders was about $16.3 million, or $(0.12) per share. Non-GAAP adjusted loss was $12.6 million, or $(0.10) per share.
For full-year 2025, revenue was $4.7 million and GAAP net loss was $58.0 million. Lucid ended 2025 with $34.7 million in cash and cash equivalents, compared with $22.4 million a year earlier.
The company highlighted a U.S. Department of Veterans Affairs contract that provides Medicare-aligned pricing of $1,938 per EsoGuard test across approximately 170 VA medical centers, and positive real-world data in nearly 12,000 at-risk patients showing a 95% technical success rate for its EsoCheck collection device.
Lucid Diagnostics files a shelf registration to offer up to $175,000,000 of common stock, preferred stock, debt securities, warrants and/or units, subject to completion. The filing includes an ATM prospectus supplement for an at-the-market program to sell up to $25,000,000 of common stock under a Sales Agreement with Maxim Group LLC. The prospectus states that unsold securities of $50,000,000 from a prior registration are folded into this filing. As context, shares outstanding were 176,945,972 as of March 20, 2026. Specific terms, distribution methods, pricing, and proceeds treatment will be provided in future prospectus supplements.
Lucid Diagnostics Inc. files its annual report describing a commercial-stage diagnostics business focused on preventing esophageal cancer in at‑risk GERD patients using its EsoGuard DNA test and EsoCheck cell collection device. The company highlights a large estimated U.S. screening market of about $60 billion, backed by ACG, AGA and NCCN guideline references to non‑endoscopic biomarker testing.
Lucid reports net losses of $58.0 million in 2025 and $45.5 million in 2024 and states there is substantial doubt about its ability to continue as a going concern beyond March 2027 without additional capital. It details heavy reliance on equity financings, convertible notes and arrangements with parent PAVmed, which still owns over 27% of the common stock and provides key services.
Recent developments include a $27.0 million equity offering in September 2025, an ATM program for up to $25.0 million of common stock (with $5.3 million sold after year‑end), a U.S. Department of Veterans Affairs contract for EsoGuard at the Medicare payment rate, Highmark Blue Cross Blue Shield coverage in New York, addition to the Russell 2000 and 3000 indexes, and real‑world data on about 12,000 patients supporting technical performance and clinical use.
Lucid Diagnostics Inc. reported that Chief Executive Officer Aklog Lishan acquired 2,170,000 shares of common stock through a restricted stock grant under the company’s 2018 Equity Plan. The grant has a single vesting date of May 20, 2029 and is subject to forfeiture if the required service period is not completed.
Following this award, Lishan directly holds 3,636,627 shares of common stock. The transaction was recorded at a price of $0.00 per share, reflecting that it is an equity compensation grant rather than an open-market purchase.
Matheis Dennis reported acquisition or exercise transactions in this Form 4 filing.
Lucid Diagnostics Inc. director Dennis Matheis reported an equity award of 123,000 shares of common stock. These shares are structured as restricted stock granted under the company’s 2018 Equity Plan and were not purchased on the open market.
The restricted stock has a single vesting date of May 20, 2029 and is subject to forfeiture if the required service period is not completed. Following this grant, Matheis directly holds 788,443 shares of Lucid Diagnostics common stock.
White Debra reported acquisition or exercise transactions in this Form 4 filing.
Lucid Diagnostics Inc. director Debra White reported receiving a grant of 123,000 shares of common stock as a restricted stock award under the company’s 2018 Equity Plan. The award was granted at $0.00 per share and increases her directly held stake to 235,800 shares after the transaction.
The restricted stock has a single vesting date of May 20, 2029 and is subject to forfeiture if the required service period is not completed, meaning she must remain in service through that date for the shares to fully vest.
Sparks Ronald M reported acquisition or exercise transactions in this Form 4 filing.
Lucid Diagnostics director Ronald M. Sparks received an equity award of 123,000 shares of common stock on February 20, 2026. The shares were granted at a price of $0.00 per share as restricted stock under the company’s 2018 Equity Plan.
Following this grant, Sparks directly owns 320,460 shares of common stock. The restricted stock has a single vesting date of May 20, 2029 and is subject to forfeiture if the required service period is not completed, meaning he must remain in service through that date to retain the award.
SOKOLOV JACQUE J reported acquisition or exercise transactions in this Form 4 filing.
Lucid Diagnostics Inc. director Jacque J. Sokolov reported an equity award of 123,000 shares of Common Stock. The shares are restricted stock granted under the company’s 2018 Equity Plan and carry a single vesting date of May 20, 2029, subject to forfeiture if the required service is not completed.
After this grant, Sokolov directly holds 320,460 shares of Lucid Diagnostics common stock.